Tin tức & Cập nhật
Lọc theo Chuyên ngành:
Ivabradine SR improves heart function in patients with HFrEF
Once-daily treatment with sustained-release (SR) ivabradine hemisulfate, alongside optimum standard therapy, results in better heart function in patients with chronic heart failure with reduced ejection fraction (HFrEF), reports a study.
Ivabradine SR improves heart function in patients with HFrEF
08 Aug 2022BP-lowering drug helps prevent Parkinson’s disease
Treatment with angiotensin receptor blockers (ARBs) appears to reduce the risk of Parkinson’s disease (PD) in patients newly diagnosed with hypertension, reports a recent study.
BP-lowering drug helps prevent Parkinson’s disease
08 Aug 2022Myocardial infarction after GI bleeding ups in-hospital mortality, resource use
A diagnosis of type 1 or type 2 myocardial infarction (MI) following hospitalization for gastrointestinal bleeding (GIB) often leads to higher in-hospital mortality and resource utilization, results of a recent US study have shown.
Myocardial infarction after GI bleeding ups in-hospital mortality, resource use
07 Aug 2022Do cardiovascular drugs worsen COVID-19 outcomes?
Cardiovascular medications, such as angiotensin-converting enzyme inhibitors (ACEIs)/angiotensin receptor blocker (ARBs) and anticoagulants, do not induce poor clinical outcomes in patients with COVID-19 and thus should not be discontinued, suggest the results of a meta-analysis.
Do cardiovascular drugs worsen COVID-19 outcomes?
03 Aug 2022VTE prevention in pregnancy: Does heparin dose matter?
In pregnant women with a history of venous thromboembolism (VTE), receipt of low-molecular-weight heparin (LMWH) at either a weight-adjusted intermediate-dose or fixed low-dose during the antepartum and postpartum periods results in similar VTE incidence, according to findings of the Highlow study. However, there was a numerically lower incidence of VTE during the postpartum period with intermediate-dose LMWH.
VTE prevention in pregnancy: Does heparin dose matter?
02 Aug 2022SGLT2 inhibitors show renal benefits vs GLP-1 RAs in T2D patients in the real world
Sodium-glucose cotransporter 2 (SGLT2) inhibitors are superior to glucagon-like peptide-1 receptor agonists (GLP-1 RAs) in reducing renal outcomes among patients with type 2 diabetes (T2D) in Hong Kong, a real-world population-based study by the University of Hong Kong has shown.